Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First do no harm. Improving drug safety through legislation and independent research.

Literature DB >> 18311170

First do no harm. Improving drug safety through legislation and independent research.

Mark Greener.

Abstract

Mesh：

Year: 2008 PMID： 18311170 PMCID： PMC2267386 DOI： 10.1038/embor.2008.17

Source DB: PubMed Journal: EMBO Rep ISSN： 1469-221X Impact factor: 8.807

× No keyword cloud information.

9 in total

1. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors: Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321

2. Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.

Authors: Mark Greener
Journal: EMBO Rep Date: 2005-03 Impact factor: 8.807

Review 3. Case reports of suspected adverse drug reactions--systematic literature survey of follow-up.

Authors: Yoon Kong Loke; Deirdre Price; Sheena Derry; Jeffrey K Aronson
Journal: BMJ Date: 2006-01-18

Review 4. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.

Authors: Robert I Misbin
Journal: Diabetes Care Date: 2007-12 Impact factor: 19.112

5. Adverse effects of inhaled corticosteroids in funded and nonfunded studies.

Authors: Antonio Nieto; Angel Mazon; Rafael Pamies; Juan J Linana; Amparo Lanuza; Fernando Oliver Jiménez; Alejandra Medina-Hernandez; F Javier Nieto
Journal: Arch Intern Med Date: 2007-10-22

6. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.

Authors: Thomas J Moore; Michael R Cohen; Curt D Furberg
Journal: Arch Intern Med Date: 2007-09-10

7. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors: C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal: N Engl J Med Date: 2000-11-23 Impact factor: 91.245

8. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Authors: Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Patrice Matchaba; Alberto Gimona; Christopher J Hawkey
Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321

9. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors: Steven E Nissen; Kathy Wolski
Journal: N Engl J Med Date: 2007-05-21 Impact factor: 91.245

9 in total

4 in total

1. Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011.

Authors: Liana Hakobyan; Flora M Haaijer-Ruskamp; Dick de Zeeuw; Daniela Dobre; Petra Denig
Journal: Drug Saf Date: 2011-12-01 Impact factor: 5.606